STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Liver-drug Approval, Pharma’s Positive Outlook, And More
The FDA granted accelerated approval for the first medicine developed specifically to treat a serious liver disease known as MASH.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About BIO Cutting Ties With WuXi, EU Pharma Rules, And More
The BIO industry trade group is cutting ties with China's WuXi in response to U.S. government scrutiny of the biotech and other Chinese companies.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Amazon Delivering Zepbound, Hemophilia Treatments, And More
Amazon Pharmacy, which has sold prescription medicines online since 2020, will now handle home delivery of the anti-obesity therapy Zepbound.
STAT1 min read
Opinion: Good Health Care Price Transparency Rules Are At Risk If Congress Doesn’t Act
Health price transparency isn’t just about consumers — it’s also about designing employee health plans that benefit everyone.
STAT1 min read
STAT+: In Large Trial, Guardant Health’s Blood Test Detects Colon Cancer, But Less Reliably At Earliest Or Precancerous Stages
If approved, Guardant Health’s liquid biopsy is likely to be a strong new addition to colorectal cancer screening tools, particularly for patients who currently choose not to get screened.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Failed Schizophrenia Drug Trial, A Pfizer Cancer Drug, And More
Acadia Pharmaceuticals disclosed that Nuplazid failed to improve the social and emotional symptoms of schizophrenia in a late-stage clinical trial.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy Approved For Heart Risks, An ALS Drug Puzzle, And More
The FDA approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its benefits for the heart, a move that could boost demand and insurance coverage.
STAT2 min read
STAT+: Eli Lilly’s Anti-vanity Ad Campaign For Oscars
Eli Lilly will be unveiling a new campaign during this weekend’s Oscar awards event, with a clear message: These drugs aren’t meant to be used for cosmetic reasons. "It matters…
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Alzheimer’s Drug Adcomm, Amylyx ALS Drug Flop, And More
In a surprise, the FDA has called for a meeting of outside advisers to discuss whether an Alzheimer’s drug from Eli Lilly should be approved.
STAT1 min read
STAT+: IVF Doctors Demand Full Details On Fluid That Grows Embryos Amid CooperSurgical Lawsuits
Patients from all over the country are filing lawsuits against medical supply giant CooperSurgical, alleging that fluid the company sent to in vitro fertilization clinics destroyed their embryos. The fluid, called culture media, is filled with nutrie
STAT1 min read
Opinion: STAT+: It’s Time To Rethink Everything About Our Approach To Psychiatric Drug Development
Can biology explain how people with the same psychiatric disorder respond differently to the same treatment?
STAT1 min read
Opinion: Free Tuition Won’t Fix Medicine’s Diversity Problem Without Admissions Reform
A second New York medical school is going tuition-free in hopes of improving diversity. But more changes are needed.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Lilly Obesity-drug Ad, A $35 Cap On Inhalers, And More
Ahead of the Oscars and amid shortages, Lilly is running a new ad campaign urging consumers against vanity use of weight-loss drugs.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About HIV Drug Resistance, March-in Rights, And More
The World Health Organization said resistance to GSK's HIV drug dolutegravir has exceeded levels observed during its clinical trials.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Ozempic Tackling Kidney Disease, OTC Birth Control, And More
Novo Nordisk’s diabetes medication Ozempic cut the risk of patients developing advanced kidney disease or dying from kidney or heart complications in a new study.
STAT1 min readAddiction
STAT+: Q&A: Nora Volkow On How To Get ‘At Least 50% Less People Dying’ From Opioid Overdose
"We’ve generated, in our country, a very different system for treating people that have problems with addiction, versus the health care system that treats everything else," says NIDA's Nora Volkow.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Nixed Medicare Negotiation Lawsuit, An Obamacare Challenge, And More
A U.S. judge in Delaware ruled against AstraZeneca on all its major arguments in a case challenging Medicare’s new drug price negotiation program.
STAT1 min read
STAT+: Up And Down The Ladder: The Latest Comings And Goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About RSV Vax Link To GSB, A Pfizer Donation, And More
In today's Pharmalittle roundup, we're reading about RSV vaccines' link to Guillain-Barré syndrome, a Pfizer donation that caught lawmakers' eyes, and more.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About White House Eyeing PBMs, Pfizer CEO’s Frustrations, And More
In today's Pharmalittle roundup, we're reading about the White House eyeing PBMs, the Pfizer CEO's frustrations, and more.
STAT1 min read
Chikungunya Vaccine Approved For Select Groups By CDC Advisory Panel
Adult travelers and researchers to regions outside the U.S. where the mosquito-borne virus is endemic may receive the vaccine, the group said Wednesday.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About The FTC Vs. PBMs, FDA Adcomm Voting And More
The U.S. FDA plans to increase the number of inspections at Indian drug manufacturers in 2024 amid growing concerns over quality issues
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Congress Punts PBM Reform, Another Obesity Drug And More
BioMarin Pharmaceutical received a subpoena from the U.S. Department of Justice seeking information about the sponsored testing programs.
STAT2 min read
STAT+: FDA Protocols Originally Intended To Be Extra Conservative Are Now Heralded As Evidence Of Mifepristone’s Risk
Decisions made by the FDA more than 20 years ago have come under heightened scrutiny thanks to a lawsuit calling for increased restrictions around the abortion pill mifepristone.
STAT2 min read
STAT+: MD Anderson Tried — And Failed — To Resolve Research Credit Dispute Between Two Scientists, New Documents Show
Whose idea was it? New documents reveal deep divide in a dispute involving Padmanee Sharma, one of MD Anderson’s most prominent scientists, and a junior researcher.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About State Moves On Drug Pricing, An Asthma Med For Kids And More
Oregon officials have suspended a portion of a contentious state law designed to bring more transparency to prescription drug pricing. It's a big victory for the pharmaceutical industry:
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Pharma Job Slowdown, Diet Drugs Boosting GDP, And More
The widespread use of new weight loss drugs in the U.S. could boost gross domestic product by 1% through a boost in workplace efficiency.
STAT1 min readSecurity
STAT+: UnitedHealth Cyberattack Impedes Pharmacies’ And Hospitals’ Ability To Process Insurance Claims
Hospitals and pharmacies are stuck in an insurance processing logjam after a cyberattack on UnitedHealth's Change Healthcare.
STAT1 min read
STAT+: Annovis Bio Delivers Candor On Its Parkinson’s Study, Even If It Doesn’t Inspire Much Confidence
Annovis Bio delivers candor on its Parkinson’s study, even if it doesn’t inspire much confidence.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About India-made Versions Of Wegovy, An RSV Vaccine Scramble, And More
Indian drugmakers aiming to grab a slice of the weight loss treatment sales pie are developing their own versions of Novo Nordisk's Wegovy.
…Or Discover Something New